TLDR
- Moderna stock jumped 177% in a single session after late-stage trial results showed its personalized mRNA melanoma vaccine reduced cancer recurrence.
- The one-day surge was the largest for an S&P 500 company in over two decades.
- Moderna’s market cap rose from around $25 billion to near $60 billion after the announcement.
- Analysts warn the hype may be running ahead of reality, with one model projecting low-single-digit billions in annual sales by 2032.
- Key concerns include high manufacturing costs, European pricing pressure, and questions about whether the vaccine will work beyond melanoma.
Moderna stock surged 177% on Wednesday after the company and partner Merck reported positive late-stage trial results for their personalized mRNA melanoma vaccine. The move was the largest single-day gain for an S&P 500 company in more than 20 years.
The stock’s market cap jumped from roughly $25 billion to near $60 billion in a single session. Combined with gains at Merck and BioNTech, which is developing its own personalized mRNA cancer vaccine, the three companies added around $80 billion in market value within days.
The trial showed that patients who received the personalized vaccine alongside Merck’s cancer drug Keytruda were less likely to see melanoma return compared to those on Keytruda alone. It marks the first successful late-stage validation of an mRNA cancer vaccine.
The vaccine works by analyzing a patient’s tumor, identifying up to 34 mutations, and training the immune system to target them. In practice, only two or three of those mutations tend to generate a meaningful immune response. Melanoma, with its high mutation count and sensitivity to immunotherapy, is a particularly good fit for this approach.
Wall Street Pumps the Brakes
Not everyone is buying the euphoria.
Analyst Daina Graybosch at Leerink Partners projects the therapy could generate low-single-digit billions in annual sales by 2032. Even in a bull case where the vaccine peaks at $10 billion per year for the Moderna-Merck partnership, that might support around $40 billion in added market value between the two companies. The market added more than that in a single afternoon.
RBC Capital Markets analyst Luca Issi notes the market is pricing in a scenario where the vaccine becomes the next Keytruda or Opdivo, drugs that worked across many cancer types. But the vaccine could prove effective in a much narrower range of tumors.
The cancers Moderna and Merck plan to target next present tougher challenges. Kidney cancer has fewer mutations to work with. Bladder cancer has a more resistant tumor environment. Pancreatic cancer is notoriously difficult to treat with immune-based therapies.
Manufacturing Costs Add Another Hurdle
Unlike traditional drugs made in large batches, this vaccine is built individually for each patient. A surgeon removes the tumor, sends it to a lab for sequencing, and a personalized mRNA shot is then manufactured. That process is expensive.
The full treatment could cost around $300,000, based on comparable therapies. That price point creates friction in European markets, where health systems negotiate hard on drug prices. The Trump administration’s push to tie U.S. drug prices to international rates could also limit pricing power at home.
Gross margins could land between 50% and 80% initially, according to Graybosch. That is well below the 90%-plus margins common for traditional drugs.
Moderna has always been a story-driven stock. The bigger long-term opportunity, analysts say, may lie in using mRNA to prevent cancer in high-risk patients before it develops. That frontier, however, remains far off.
Moderna’s market cap stood near $60 billion at the end of last week, up from about $25 billion before Wednesday’s announcement.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
